×

Scientific Publications

Dr. S.R. Burzynski and his associates continuously report new scientific information. The following is a list of publications that excludes articles published before 2010.

 Targeted Therapy

  • Burzynski S.R., Janicki T. J., Beenken S, Treatment of Recurrent Glioblastoma Multiforme (RGBM) with Antineoplaston AS2-1 In Combination With Targeted Therapy. Cancer and Clinical Oncology 2019;8:1-15
  • Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.
  • Burzynski, S.R., Burzynski, G.S. Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.
  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.
  • Burzynski, S.R, Nagy-Kubove, E.Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.

CLINICAL TRIALS

  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors. Final report (Protocol BT-10). J Cancer Ther 2017; 8:173-187.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma. Final report for Protocol with BT-23. Cancer Clin Oncol 2017; 6(1):25-35.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1. Cancer Clin Oncol 2016; 5(2):38-48.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas-Final report (Protocol BT-13). J Cancer Ther 2016; 7(12):837-850.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin Oncol 2015; 4(2):41-52.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with primary brain tumors-Final report (Protocol BT-09). J Cancer Ther 2015; 6(12):1063-1074.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer Clin Oncol 2015;442:13-23.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas. The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer ClinOncol 2015;4(1):28-38.
  • Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;5:946-956.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;5:977-988.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child’s Nervous System 2014;30(12):2051-2061.
  • Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004. Neuro-Oncology 2014;16(Suppl. 1):i10
  • Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020. Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in pediatric recurrent diffuse intrinsic pontine glioma. NO-021. Neuro-Oncology 2013;15(Suppl. 3):iii103.
  • Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 (ANP) in children with high-grade glioma (Protocol BT-06). NO-058. Neuro-Oncology 2013;15(Suppl. 3):iii112.

CASE REPORTS

  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca. J.F. Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J. Neurol Stroke 2015;2(6):00072.
  • Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca. J.F. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with antineoplastons A10 and AS2-1. J. Neurol Stroke 2015;2(3):00054.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Complete response and long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg 2015;50(2):99-103.
  • Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015; 6:40-44.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi:10.1097/MPH.0000000000000020.
  • Janicki, T.J., Burzynski, G.S., Burzynski, S.R. Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.
  • Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R. Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro Oncol 2014;16(Suppl. 5):v175.
  • Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi: 10.1097/MPH.0000000000000020.
  • Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017. Neuro-Oncology 2014;16(Suppl. 1):i44.
  • Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020. Neuro-Oncology 2014;16(Suppl. 1):i80.
  • Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089. Neuro-Oncology 2013;15(Suppl. 3):iii120.
  • Burzynski, S.R., Nagy-Kubove, E. Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.
  • Burzynski, S.R., Marquis, A., Nagy-Kubove, E., Janicki, T.J. Successful treatment of recurrent triple-negative breast cancer with combination of targeted therapies. Journal of Cancer Therapy 2011;2:372-376.

REVIEW ARTICLES

  • Burzynski, S.R. Stanislaw R. Burzynski, MD, PhD: Novel cancer research and the fight to prove its worth. Alternative Therapies in Health and Medicine 2012;18(3):54-61.

BASIC SCIENCE

  • Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J. Cancer Ther 2014;5:929-945.
  • Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;5:929-945.
  • Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. SystBiol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.
  • Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer.  Drug Designing 2013;2(1):103.
  • Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutaminate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200.
  • Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chitur, S.V. Phenylacetylglutaminate and phenylacetate in combination upregulate VDUPI, cause cell cycle blockade and apoptosis in U87 glioblastoma cells, Journal of Cancer Therapy 2012;3:192-200.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Neuro-Oncology 2010;12(Suppl. 4):iv10.
  • Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing surviving expression in U87 glioblastoma cells. Neuro-Oncology 2010;12(6):ii87.

THEORETICAL ARTICLES

  • Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.

INDEPENDENT AUTHORS

  • Ogata Y, Matono K, Tsuda H, Ushijima M, Uchida S, Akagi Y, Shirouzu K. Randomized phase II study of 5-fluorouracil hepatic arterial infusion with or without Antineoplastons as an adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. PLoS ONE 2015;10(3):e012064. Doi:10.1371/journal.pone.0120064
  • Ushijima M, Ogata Y, Tsuda H, Akagi Y, Matono K, Shirouzu K.  Demethylation effect of the antineoplaston AS2-1 on genes in colon cancer cells. Oncology Report 2014;31:19-26.
  • Ogata Y, Shirouzu K, Matono K, Ushijima S, Uchida S, Tsuda H.  Randomized phase II study of hepatic arterial infusion with or without Antineoplastons as adjuvant therapy after hepatectomy for liver metastases from colorectal cancer.  Ann Oncol 2010;21.

Request an Appointment

Copyright ©2024 All Rights Reserved